Do patients with von Willebrand disease exhibit higher blood loss and revision rates in hip and knee arthroplasty? A case-control study.
blood loss
complications
hip arthroplasty
knee arthroplasty
von Willebrand disease
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
09
01
2020
revised:
26
02
2020
accepted:
26
02
2020
pubmed:
12
3
2020
medline:
15
12
2020
entrez:
12
3
2020
Statut:
ppublish
Résumé
The aim of the study was to compare the perioperative blood loss, need for transfusion and one-year revision rates in patients undergoing hip and knee arthroplasty who also have a diagnosis of von Willebrand disease (VWD) with a matched control group. A retrospective single-centre case-control study was conducted. Fifty-eight patients with VWD and 116 controls (1:2 match) who were operated for primary or revision hip and knee arthroplasty at our hospital were included. Blood loss, haemoglobin (Hb)-drop, need for blood transfusion, intraoperative complications and revision rates within one year were noted in all cases. Outcome measures for subgroups of the primary hip, primary knee, revision hip and revision knee procedures, were also analysed. The mean perioperative Hb-drop was 3.47 (±1.27) g/dL and blood loss was 293 (±97) ml for the VWD group while Hb-drop was 2.85 (±1.21) g/dL and blood loss was 232 (±105) mL for the control group (P < .001). There were no significant increased transfusion rates (P = .264) and revision rates in the VWD group (P = .634). Patients having primary hip surgery had significantly higher Hb-drop (3.68 ± 1.25 g/dL vs 2.62 ± 1.19 g/dL; P = .003), higher blood loss (293 vs 203 mL; P = .002) and increased need for a transfusion (21% vs 2.6%; P = .038) compared to the controls. No outcome measure was found to be significantly different for primary and revision knee surgery. The results of this study suggest that patients with VWD undergoing primary or revision total hip and knee arthroplasty have higher levels of blood loss than the control cohort. Perioperative protective measures including meticulous surgical techniques should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the study was to compare the perioperative blood loss, need for transfusion and one-year revision rates in patients undergoing hip and knee arthroplasty who also have a diagnosis of von Willebrand disease (VWD) with a matched control group.
METHODS
METHODS
A retrospective single-centre case-control study was conducted. Fifty-eight patients with VWD and 116 controls (1:2 match) who were operated for primary or revision hip and knee arthroplasty at our hospital were included. Blood loss, haemoglobin (Hb)-drop, need for blood transfusion, intraoperative complications and revision rates within one year were noted in all cases. Outcome measures for subgroups of the primary hip, primary knee, revision hip and revision knee procedures, were also analysed.
RESULTS
RESULTS
The mean perioperative Hb-drop was 3.47 (±1.27) g/dL and blood loss was 293 (±97) ml for the VWD group while Hb-drop was 2.85 (±1.21) g/dL and blood loss was 232 (±105) mL for the control group (P < .001). There were no significant increased transfusion rates (P = .264) and revision rates in the VWD group (P = .634). Patients having primary hip surgery had significantly higher Hb-drop (3.68 ± 1.25 g/dL vs 2.62 ± 1.19 g/dL; P = .003), higher blood loss (293 vs 203 mL; P = .002) and increased need for a transfusion (21% vs 2.6%; P = .038) compared to the controls. No outcome measure was found to be significantly different for primary and revision knee surgery.
CONCLUSIONS
CONCLUSIONS
The results of this study suggest that patients with VWD undergoing primary or revision total hip and knee arthroplasty have higher levels of blood loss than the control cohort. Perioperative protective measures including meticulous surgical techniques should be considered.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-519Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454-459.
Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-898.
Chapin J. Von Willebrand disease in the elderly : clinical perspectives. Clin Interv Aging. 2018;13:1531-1541.
Manco-Johnson M, Lundin B, Funk S, Peterfy C, Raunig D, Werk M. Effect of late prophylaxis in hemophilia on joint status : a randomized trial. J Thromb Haemost. 2017;15:2115-2124.
Cancienne JM, Werner BC, Browne JA. Complications after TKA in patients with Hemophilia or Von Willebrand’s disease. J Arthroplasty. 2015;30(12):2285-2289.
Coppola M, Franchini M, Makris E, Santagostino GD, Di minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):1-15.
Habermann C, Eberhardt L, Hovy L, Zichner L, Scharrer I, Kurth AA. Total hip replacement in patients with severe bleeding disorders: a 30 years single center experience. Int Orthop. 2007;31(1):17-21.
Kotela M, Wilk-Frańczuk P, Żbikowski P, Łęgosz PA, Kotela I. Revision knee arthroplasty in patients with inherited bleeding disorders: a single-center experience. Med. Sci. Monit. 2017;23:129-137.
Strauss C, Rommelspacher Y, Nouri B, et al. Long-term outcome of total hip arthroplasty in patients with haemophilia. Haemophilia. 2017;23(1):129-134.
Barg K, Wiewiorski M, Anderson AE, et al. Total ankle replacement in patients with von Willebrand disease: Mid-term results of 18 procedures. Haemophilia. 2015;21(5):e389-e401.
Rugeri L, Ashrani AA, Nichols WL, Trousdale RT, Pruthi RK. A single-centre study of haemostatic outcomes of joint replacement in von Willebrand disease and control patients and an analysis of the literature. Haemophilia. 2016;22(6):934-942.
Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease : a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
Tammachote N, Kanitnate S. Electric cautery does not reduce blood loss in primary total knee arthroplasty compared with scalpel only surgery a double-blinded randomized controlled trial. Int Orthop. 2018; 42, 2755-2760.
Meunier A, Petersson A, Good L, Berlin G. Validation of a haemoglobin dilution method for estimation of blood loss. Vox Sang. 2008;95(2):120-124.
Puvanesarajah V, Jain A, Shimer AL, Shen FH, Hassanzadeh H. The effect of coagulopathies on perioperative complications and clinical outcomes in patients treated with posterior lumbar fusions. Spine J. 2016; 41(17): E1063-E1068.
Westberg M, Paus AC, Holme PA, Tjønnfjord GE. Haemophilic arthropathy: Long-term outcomes in 107 primary total knee arthroplasties. Knee. 2014;21(1):147-150.
Pugely J, Martin CT, Gao Y, Schweizer ML, Callaghan JJ. The incidence of and risk factors for 30-day surgical site infections following primary and revision total joint arthroplasty. J. Arthroplasty. 2015;30(9):47-50.
Strauss C, Rommelspacher Y, Nouri B, et al. Long-term outcome of total hip arthroplasty in patients with haemophilia. Haemophilia. 2017;23(1):129-134.
Rodriguez-Merchan EC, Romero-Garrido JA, Gomez-Cardero P. Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A. Haemophilia. 2016;22(4):e318-e320.
Carlos Rodriguez-Merchan E. What´s New in Orthopedic Surgery for People with Hemophilia. Arch Bone Jt Surg. 2018;6(3):157-160.
Pradhan SM, Key NS, Boggio L, Pruthi R. Venous thrombosis prophylaxis in haemophilics undergoing major orthopaedic surgery: a survey of haemophilia treatment centres. Haemophilia. 2009; 15(6): 1337-1338.
Govorov I, Löfgren S, Chaireti R, Holmström M, Bremme K, Mints M. Postpartum hemorrhage in women with von Willebrand disease - A retrospective observational study. PLoS One. 2016;11(10):1-14.
van Galen PM, Mauser-Bunschoten EP, Leebeek FWG. Hemophilic arthropathy in patients with von Willebrand disease. Blood Rev. 2012;26(6):261-266.
Rosencher N, Kerkkamp HEM, Macheras G, et al. Orthopedic surgery transfusion hemoglobin european overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):303-327.
Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty. 2014;29(9 SUPPL.):189-192.
Magill P, Cunningham EL, Hill JC, Beverland DE. Identifying the period of greatest blood loss after lower limb arthroplasty. Arthroplast Today. 2018;4(4):499-504.
Jawhar A, Skeirek D, Stetzelberger V, Obertacke U Influence of the tourniquet on pain and function in total knee arthroplasty: a systematic review and meta-analysisZ Orthop Unfall. 2019.
Lavin M, O’Donnell JS. New treatment approaches to von Willebrand disease. Hematology. 2016;2016(1):683-689.
Saccullo G, Makris M. Prophylaxis in von Willebrand disease: coming of age? Semin Thromb Hemost. 2016;42(5):498-506.